Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a megadeal that signals how aggressively big pharma is now chasing ...

Jack O’Meara stands outside wearing a dark-blue pullover Jack O’Meara is the CEO and cofounder of Aerska. Credit: Aerska A group of RNA veterans is launching a new start-up aimed at getting ...

Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life ...

Our brain is a fortress. Its delicate interior is completely surrounded by a protective wall called the blood-brain barrier. True to its name, the barrier separates contents in the blood and the brain ...

The right approaches are demonstrating that it is possible to breach the defensively designed blood-brain barrier despite its ...

The highly selective border lining the brain’s vasculature is the Achilles’ heel of any large therapeutic molecule aiming for targets in the brain, anti-Aβ antibodies included. Not only do fewer than ...

Vect-Horus has a clinical-phase solution to a key drug development challenge: crossing the blood–brain barrier (BBB). By targeting receptors on the barrier, Vect-Horus is empowering partners such as ...